Physicians prefer greater detail in the biosimilar label (SmPC) - Results of a survey across seven European countries

- Physicians across Europe were surveyed about preferences on information sources.
- The label is among the most frequently consulted sources for information on biologics.
- Clinical particulars and Pharmacological properties rated most important sections.
- The majority prefers a modified label for biosimilars providing more information.
- Clear statement(s) on the origin of the data were considered most helpful.

In the European Union, labels (Summaries of Product Characteristics, SmPCs) of biosimilars and their reference products are in many instances almost identical (following a generic approach) despite different data requirements for the authorization of biosimilars and generics. To understand physicians' preferences on type and detail of information in the biosimilar label and their use of information sources when prescribing biologics including biosimilars, EuropaBio surveyed 210 physicians across seven European countries. Among surveyed physicians, 90.5% use the label frequently or occasionally as an information source and 87.2% deemed a clear statement on the origin of data helpful or very helpful. When comparing excerpts from the label of an authorized biosimilar and modified texts with additional information, 78.1-82.9% preferred the samples with additional information. This survey shows that the label is an appropriate vehicle for providing physicians with information about biologics and that physicians prefer more product-specific information in the biosimilar label.